The editors of Cancer: Principles and Practice of Oncology (PPO) made two radical departures in the format of this edition from all other previous editions. The changes were driven by the evolving understanding of cancer biology and its applicability to Clinical Oncology and the ever-changing reading habits of our readership. They were foretold by innovations in the 11 prior editions of the text. The original plan that has driven PPO to the ranks of the most popular cancer text in the world was to divide the text into two major parts: the first section covering the science of Oncology (The Principles), the second the practice of Oncology, with each chapter in the practice section written by at least three authors representing the three major approaches to therapy—surgery, medical, and radiation—emphasizing treatment by stage. In 1982, when the first edition was published, there were no multidisciplinary cancer texts available. While the basic science was bountiful, its applicability to clinical practice was spotty. By combining principles and practice of oncology in one text, the readers could see for themselves what was known and what was considered the best practice of cancer medicine. The clinical application of basic information on cancer has vastly accelerated since then and the changes have been closely mirrored in subsequent editions. The presentation of information on molecular biology of cancer is a good example. Up until the fourth edition in 1993, information on the molecular biology of cancer was scattered throughout the text. In 1997, with the publication of the fifth edition, the editors saw a compelling reason to collect information on molecular biology by tumor type and place it in a separate chapter preceding each main disease-oriented chapter, providing readers with a convenient collection of relevant information prepared by a different group of authors. This change was well received. This practice continued for the next five editions, leavened in later editions by editorial ambivalence, with some major disease chapters having molecular biology embedded in the main chapters and others not. With the 10th (2015) and 11th (2019) editions, we faced a problem with redundancy, as so much basic information had become relevant to clinical practice that the same information was being presented as many as three times: in the first section, in the molecular biology chapters, and, despite urgings by the editors to leave the science to the relevant chapters, in the chapters on clinical practice. With the advent of targeted therapy and immunotherapy, they needed to be together. The same trend was noted in other areas, such as cancer diagnostics, immunology and immunotherapy, and genetic counseling, to name a few. Of course, this is good news. In this edition, the first major departure in format reflects this trend by moving all the relevant science into the major disease chapters. The text is still principles and practice of oncology, but both principles and practice are in each disease-oriented chapter. The elimination of redundancy has also resulted in a smaller, single-volume text. The change in this 12th edition to minimize its size is a change to emphasizing information the clinician needs at the point of care with a reduction in the comprehensive historical backgrounds that were present in prior editions. Everyone is aware that an increasing number of readers prefer to read online. We have accommodated these readers by first issuing a CD with each text in the sixth (2000) and seventh (2005) editions and going online in a fully searchable format in the eighth (2008) edition. Despite the fact that the text is published on an average of every 3.5 years, the field is changing at a dizzying pace and much valuable information appears between formal editions. In the ninth edition, to keep the text continuously fresh, we instituted quarterly electronic updates in the online version for all the disease chapters. These updates are inserted, in highlighted form, in the appropriate places in each chapter. The online version is available to all who purchase the book. PPO is the only cancer text that is continuously updated online. The second major departure relates to convenience of reading a text. And, believe it or not, there are still a substantial number of doctors who prefer to read the print version of the book. While the single volume of PPO 12 will be smaller, it will still be a big book. The editors have often heard from readers complaining about the size and weight of the book. “I love the book, but it is never where I am and it’s too heavy to carry” is a comment that comes to mind. So, we thought we would try a publishing experiment and divide the book into a package of seven soft cover volumes, each easy to carry, and publish both the smaller single volume and the seven-volume package, giving book readers the option to choose the format that will best suit them. The content of the new edition is filled, of course, with the many exciting new advances relevant to practice, such as new approaches to targeted therapy and immunotherapy, both of which have become effective new tools in the systemic therapy toolbox. This is especially true in lung cancer and melanoma but also, happily, in many other tumors—especially lymphoid malignancies, for which adoptive genetically modified cell therapy promises to make immunotherapy applicable to many tumor types. All these approaches are chronicled in the new PPO 12. With lessons learned from the COVID-19 pandemic, the use of telemedicine in oncology is also a new addition to the book. As is our usual practice, we rotate about a third of the authors to offer readers a fresh point of view. These are exciting times in cancer medicine. We hope you enjoy the new PPO as much as we enjoyed editing it.